Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Jefferies ups rating on M&S, downgrades Sainsbury's

(Sharecast News) - Jefferies has upgraded Marks & Spencer Group and downgraded J Sainsbury in a note published on Thursday assessing the UK general retail sector. The bank upped its recommendation on M&S to 'buy' from 'hold', despite the blue chip being hit by a major cyberattack.

Jefferies said: "The business continues to demonstrate strong fundamental growth in a buoyant UK consumer environment, buyside expectations for profit delivery in 2025/26 have moderated to more sustainable levels [and] we find no evidence at this stage that the cyberattack will impact medium-term share gains."

It also upped the price target, to 440p from 370p.

But it opted to cut Sainsbury's rating to 'hold' from 'buy', citing recent share price gains.

Jefferies said: "Our view of Sainsbury's market share opportunities in 2025/26 remains unchanged, but recent [share price] outperformance limits near-term upside.

"We continue to see Sainsbury's food space growth and elevated cost save programme offering space for earnings resilience this year.

"Our move to 'hold' entirely reflects the shares' recent outperformance, with our estimates and price target unchanged."

Jefferies has a price target of 300p on Sainsbury's.

As at 1330 BST, M&S was trading 2% higher at 380.5p, while Sainsbury's was nearly 1% lower at 286.4p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.